Votrient® Sarcoma Named Patient Programme Chart Review (SPIRE)
Research type
Research Study
Full title
Votrient® Sarcoma Named Patient Programme Chart Review (SPIRE)
IRAS ID
142708
Contact name
Ian Judson
Contact email
Sponsor organisation
GSK
Research summary
This is a multicentre, observational retrospective chart review study of treatment patterns in a subset of patients with advanced soft tissue sarcoma (aSTS) who received pazopanib as part of the Named Patient Programme (NPP). \n\nThis study requires no intervention or interference with standard medical care, and thus it will not affect patient treatment.\n\nCharts of patients who received pazopanib as part of the NPP (August 2011- August 2013 across all participating countries) will be identified by site staff. Each identified patient will be assigned a pre-formatted unique study identification number. Site staff will review the medical charts for all identified patients to determine patient eligibility. Those patients who meet eligibility criteria will be enrolled into the final study cohort as subjects. Data will be pseudonymised. Data will be captured using the electronic data capture (EDC) system
REC name
East of England - Cambridgeshire and Hertfordshire Research Ethics Committee
REC reference
13/EE/0450
Date of REC Opinion
11 Dec 2013
REC opinion
Favourable Opinion